Could a common steroid save lives in severe sepsis and lung failure?

NCT ID NCT07511582

Not yet recruiting Disease control Sponsor: Bin Du Source: ClinicalTrials.gov ↗

First seen Apr 18, 2026 · Last updated Apr 28, 2026 · Updated 4 times

Summary

This study tests whether the steroid methylprednisolone can improve organ function and reduce deaths in critically ill patients with a severe inflammatory condition called hyperinflammatory phenotype, often seen in sepsis and acute respiratory distress syndrome (ARDS). About 150 adults in intensive care will receive either a high or low dose of the drug or a placebo for up to 7 days. Researchers will monitor organ function, survival, and recovery for 30 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.